QQQ   423.96 (-0.44%)
AAPL   167.03 (-0.58%)
MSFT   405.71 (-1.49%)
META   502.21 (+1.63%)
GOOGL   156.42 (+0.61%)
AMZN   179.33 (-1.08%)
TSLA   151.18 (-2.75%)
NVDA   848.14 (+0.93%)
AMD   154.95 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.25 (+0.81%)
F   12.02 (-0.17%)
MU   112.71 (-3.11%)
GE   153.81 (-1.19%)
CGC   8.02 (+23.57%)
DIS   113.03 (+0.08%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.20 (-1.68%)
XOM   118.34 (-0.24%)
QQQ   423.96 (-0.44%)
AAPL   167.03 (-0.58%)
MSFT   405.71 (-1.49%)
META   502.21 (+1.63%)
GOOGL   156.42 (+0.61%)
AMZN   179.33 (-1.08%)
TSLA   151.18 (-2.75%)
NVDA   848.14 (+0.93%)
AMD   154.95 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.25 (+0.81%)
F   12.02 (-0.17%)
MU   112.71 (-3.11%)
GE   153.81 (-1.19%)
CGC   8.02 (+23.57%)
DIS   113.03 (+0.08%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.20 (-1.68%)
XOM   118.34 (-0.24%)
QQQ   423.96 (-0.44%)
AAPL   167.03 (-0.58%)
MSFT   405.71 (-1.49%)
META   502.21 (+1.63%)
GOOGL   156.42 (+0.61%)
AMZN   179.33 (-1.08%)
TSLA   151.18 (-2.75%)
NVDA   848.14 (+0.93%)
AMD   154.95 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.25 (+0.81%)
F   12.02 (-0.17%)
MU   112.71 (-3.11%)
GE   153.81 (-1.19%)
CGC   8.02 (+23.57%)
DIS   113.03 (+0.08%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.20 (-1.68%)
XOM   118.34 (-0.24%)
QQQ   423.96 (-0.44%)
AAPL   167.03 (-0.58%)
MSFT   405.71 (-1.49%)
META   502.21 (+1.63%)
GOOGL   156.42 (+0.61%)
AMZN   179.33 (-1.08%)
TSLA   151.18 (-2.75%)
NVDA   848.14 (+0.93%)
AMD   154.95 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.25 (+0.81%)
F   12.02 (-0.17%)
MU   112.71 (-3.11%)
GE   153.81 (-1.19%)
CGC   8.02 (+23.57%)
DIS   113.03 (+0.08%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.20 (-1.68%)
XOM   118.34 (-0.24%)
NASDAQ:SLP

Simulations Plus (SLP) Stock Price, News & Analysis

$44.48
-0.22 (-0.49%)
(As of 03:15 PM ET)
Today's Range
$44.45
$45.55
50-Day Range
$38.46
$50.73
52-Week Range
$32.69
$52.69
Volume
42,301 shs
Average Volume
109,582 shs
Market Capitalization
$889.16 million
P/E Ratio
83.92
Dividend Yield
0.54%
Price Target
$53.00

Simulations Plus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
18.8% Upside
$53.00 Price Target
Short Interest
Bearish
7.40% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.45mentions of Simulations Plus in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.52 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.77 out of 5 stars

Computer And Technology Sector

408th out of 587 stocks

Computer Integrated Systems Design Industry

21st out of 35 stocks

SLP stock logo

About Simulations Plus Stock (NASDAQ:SLP)

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

SLP Stock Price History

SLP Stock News Headlines

Simulations Plus Inc.
Nvidia Has a BIG Problem — Here’s Who Benefits MOST
#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'
SLP Sep 2024 55.000 call
Nvidia Has a BIG Problem — Here’s Who Benefits MOST
#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'
Q2 2024 Simulations Plus Inc Earnings Call
Simulations Plus: Fiscal Q2 Earnings Snapshot
SLP Apr 2024 40.000 put
See More Headlines
Receive SLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Simulations Plus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/5 Dividend
1/26/2024
Dividend Payable
2/05/2024
Last Earnings
4/03/2024
Today
4/18/2024
Ex-Dividend for 5/6 Dividend
4/26/2024
Dividend Payable
5/06/2024
Next Earnings (Estimated)
7/04/2024
Fiscal Year End
8/31/2024

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
N/A
Current Symbol
NASDAQ:SLP
Employees
192
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$53.00
High Stock Price Target
$55.00
Low Stock Price Target
$51.00
Potential Upside/Downside
+18.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$9.96 million
Pretax Margin
19.60%

Debt

Sales & Book Value

Annual Sales
$59.58 million
Cash Flow
$0.82 per share
Book Value
$8.86 per share

Miscellaneous

Free Float
15,808,000
Market Cap
$893.55 million
Optionable
Optionable
Beta
0.72

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Walter S. Woltosz M.A.S. (Age 79)
    M.S., Co-Founder & Chairman
    Comp: $80k
  • Mr. Shawn M. O'Connor (Age 64)
    Chief Executive Officer
    Comp: $847.56k
  • Mr. William Frederick (Age 60)
    COO, CFO & Secretary
    Comp: $443.12k
  • Mr. John Anthony DiBella M.S. (Age 44)
    President of PBPK & Cheminformatics Solutions
    Comp: $399.8k
  • Dr. Brett A. Howell Ph.D. (Age 40)
    President of Quantitative Systems Pharmacology Solutions
    Comp: $321.67k
  • Ms. Jill Fiedler-Kelly M.S. (Age 55)
    President of Clinical Pharmacology & Pharmacometrics Services
    Comp: $393.77k
  • Ms. Viera Lukacova Ph.D.
    Chief Science Officer
  • Dr. Bud Nelson J.D.
    Ph.D., VP of Corporate Counsel & Personal Data Protection Officer
  • Ms. Arlene Padron
    Corporate Director of Marketing
  • Ms. Lindsay Luke
    Executive Director of Human Resources

SLP Stock Analysis - Frequently Asked Questions

Should I buy or sell Simulations Plus stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Simulations Plus in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLP shares.
View SLP analyst ratings
or view top-rated stocks.

What is Simulations Plus' stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for Simulations Plus' shares. Their SLP share price targets range from $51.00 to $55.00. On average, they predict the company's stock price to reach $53.00 in the next twelve months. This suggests a possible upside of 18.8% from the stock's current price.
View analysts price targets for SLP
or view top-rated stocks among Wall Street analysts.

How have SLP shares performed in 2024?

Simulations Plus' stock was trading at $44.75 at the beginning of the year. Since then, SLP stock has decreased by 0.3% and is now trading at $44.61.
View the best growth stocks for 2024 here
.

When is Simulations Plus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024.
View our SLP earnings forecast
.

How were Simulations Plus' earnings last quarter?

Simulations Plus, Inc. (NASDAQ:SLP) released its quarterly earnings results on Wednesday, April, 3rd. The technology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. The technology company earned $18.31 million during the quarter, compared to analyst estimates of $17.31 million. Simulations Plus had a net margin of 16.22% and a trailing twelve-month return on equity of 7.95%. Simulations Plus's quarterly revenue was up 16.2% on a year-over-year basis. During the same period last year, the company earned $0.20 earnings per share.

How often does Simulations Plus pay dividends? What is the dividend yield for Simulations Plus?

Simulations Plus declared a quarterly dividend on Wednesday, April 3rd. Shareholders of record on Monday, April 29th will be paid a dividend of $0.06 per share on Monday, May 6th. This represents a $0.24 annualized dividend and a dividend yield of 0.54%. The ex-dividend date is Friday, April 26th.
Read our dividend analysis for SLP
.

Is Simulations Plus a good dividend stock?

Simulations Plus (NASDAQ:SLP) pays an annual dividend of $0.24 per share and currently has a dividend yield of 0.53%. The dividend payout ratio is 45.28%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for SLP.

What ETFs hold Simulations Plus' stock?

ETFs with the largest weight of Simulations Plus (NASDAQ:SLP) stock in their portfolio include AdvisorShares Insiders Advantage ETF (SURE) and Franklin Genomic Advancements ETF (HELX).Syntax Stratified SmallCap ETF (SSLY).

What guidance has Simulations Plus issued on next quarter's earnings?

Simulations Plus updated its FY 2024 earnings guidance on Wednesday, April, 3rd. The company provided EPS guidance of 0.660-0.680 for the period, compared to the consensus estimate of 0.660. The company issued revenue guidance of $66.0 million-$69.0 million, compared to the consensus revenue estimate of $67.2 million.

What other stocks do shareholders of Simulations Plus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Simulations Plus investors own include Advanced Micro Devices (AMD), Cisco Systems (CSCO), Gilead Sciences (GILD), QUALCOMM (QCOM), NVIDIA (NVDA), Verizon Communications (VZ), CVS Health (CVS), Enterprise Products Partners (EPD), AbbVie (ABBV) and Pfizer (PFE).

Who are Simulations Plus' major shareholders?

Simulations Plus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.86%), Hennion & Walsh Asset Management Inc. (0.18%) and Chatham Capital Group Inc. (0.17%). Insiders that own company stock include John Anthony Dibella II, John Kenneth Paglia, Lisa Lavange, Walter S Woltosz and Walter S Woltosz.
View institutional ownership trends
.

How do I buy shares of Simulations Plus?

Shares of SLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners